Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain | Zendy

Jijun Xu | Zendy; Philippe Diaz | Zendy; Fanny AstrucDiaz | Zendy; Suzanne Craig | Zendy; Elizandro Muñoz | Zendy; Mohamed Naguib | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain

Author(s) -

Jijun Xu,

Philippe Diaz,

Fanny AstrucDiaz,

Suzanne Craig,

Elizandro Muñoz,

Mohamed Naguib

Publication year - 2010

Publication title -

anesthesia and analgesia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.404

H-Index - 201

eISSN - 1526-7598

pISSN - 0003-2999

DOI - 10.1213/ane.0b013e3181e0cdaf

Subject(s) - medicine , neuropathic pain , cannabinoid , cannabinoid receptor , ligand (biochemistry) , pharmacology , anesthesia , neuroscience , receptor , antagonist , biology

Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N'-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide (MDA19), a CB2 agonist.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research